These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 16256250)

  • 21. Immunogenicity of 23-valent pneumococcal polysaccharide vaccine in HIV-infected pregnant women and kinetics of passively acquired antibodies in young infants.
    Almeida Vde C; Mussi-Pinhata MM; De Souza CB; Kubo CA; Martinez EZ; Carneiro-Sampaio MM; Duarte G
    Vaccine; 2009 Jun; 27(29):3856-61. PubMed ID: 19443091
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cross-sectional study of nasopharyngeal carriage of Streptococcus pneumoniae in human immunodeficiency virus-infected adults in the conjugate vaccine era.
    Onwubiko C; Swiatlo E; McDaniel LS
    J Clin Microbiol; 2008 Nov; 46(11):3621-5. PubMed ID: 18845823
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Validation of current joint American Academy of Allergy, Asthma & Immunology and American College of Allergy, Asthma and Immunology guidelines for antibody response to the 23-valent pneumococcal vaccine using a population of HIV-infected children.
    Kamchaisatian W; Wanwatsuntikul W; Sleasman JW; Tangsinmankong N
    J Allergy Clin Immunol; 2006 Dec; 118(6):1336-41. PubMed ID: 17157665
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Supplementation with zinc, but not vitamin A, improves seroconversion to vibriocidal antibody in children given an oral cholera vaccine.
    Albert MJ; Qadri F; Wahed MA; Ahmed T; Rahman AS; Ahmed F; Bhuiyan NA; Zaman K; Baqui AH; Clemens JD; Black RE
    J Infect Dis; 2003 Mar; 187(6):909-13. PubMed ID: 12660937
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Immunogenicity and boosting after a reduced number of doses of a pneumococcal conjugate vaccine in infants and toddlers.
    Goldblatt D; Southern J; Ashton L; Richmond P; Burbidge P; Tasevska J; Crowley-Luke A; Andrews N; Morris R; Borrow R; Cartwright K; Miller E
    Pediatr Infect Dis J; 2006 Apr; 25(4):312-9. PubMed ID: 16567982
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Development of 5-valent conjugate pneumococcal protein A - Capsular polysaccharide pneumococcal vaccine against invasive pneumococcal disease.
    Meng C; Lin H; Huang J; Wang H; Cai Q; Fang L; Guo Y
    Microb Pathog; 2009 Sep; 47(3):151-6. PubMed ID: 19467319
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Phase 1 trial of a 13-valent pneumococcal conjugate vaccine in healthy adults.
    Scott DA; Komjathy SF; Hu BT; Baker S; Supan LA; Monahan CA; Gruber W; Siber GR; Lockhart SP
    Vaccine; 2007 Aug; 25(33):6164-6. PubMed ID: 17629361
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immunogenicity and safety of pneumococcal 7-valent conjugate vaccine (diphtheria CRM(197) protein conjugate; Prevenar ) in Korean infants: differences that are found in Asian children.
    Kim NH; Lee J; Lee SJ; Lee H; Kim KH; Park SE; Lee HJ
    Vaccine; 2007 Nov; 25(45):7858-65. PubMed ID: 17931753
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Randomised revaccination with pneumococcal polysaccharide or conjugate vaccine in asplenic children previously vaccinated with polysaccharide vaccine.
    Smets F; Bourgois A; Vermylen C; Brichard B; Slacmuylders P; Leyman S; Sokal E
    Vaccine; 2007 Jul; 25(29):5278-82. PubMed ID: 17576024
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immunogenicity of sequential pneumococcal vaccination in subjects splenectomised for hereditary spherocytosis.
    Stoehr GA; Rose MA; Eber SW; Heidemann K; Schubert R; Zielen S
    Br J Haematol; 2006 Mar; 132(6):788-90. PubMed ID: 16487181
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Kinetics of the immune response following pneumococcal PD conjugate vaccination.
    Schuerman L; Prymula R; Chrobok V; Dieussaert I; Poolman J
    Vaccine; 2007 Mar; 25(11):1953-61. PubMed ID: 17258358
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immunization with the 7-valent conjugate pneumococcal vaccine: impact evaluation, continuing surveillance and future perspectives.
    Bechini A; Boccalini S; Bonanni P
    Vaccine; 2009 May; 27(25-26):3285-90. PubMed ID: 19200829
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immunogenicity and safety of a combination diphtheria, tetanus toxoid, acellular pertussis, hepatitis B, and inactivated poliovirus vaccine coadministered with a 7-valent pneumococcal conjugate vaccine and a Haemophilus influenzae type b conjugate vaccine.
    Pichichero ME; Bernstein H; Blatter MM; Schuerman L; Cheuvart B; Holmes SJ;
    J Pediatr; 2007 Jul; 151(1):43-9, 49.e1-2. PubMed ID: 17586189
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immunogenicity and safety of measles-mumps-rubella, varicella and Haemophilus influenzae type b vaccines administered concurrently with a fourth dose of heptavalent pneumococcal conjugate vaccine compared with the vaccines administered without heptavalent pneumococcal conjugate vaccine.
    Black SB; Cimino CO; Hansen J; Lewis E; Ray P; Corsaro B; Graepel J; Laufer D
    Pediatr Infect Dis J; 2006 Apr; 25(4):306-11. PubMed ID: 16567981
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Functional activity of antibodies after immunization of Finnish and Israeli infants with an 11-valent pneumococcal conjugate vaccine.
    Wuorimaa TK; Dagan R; Bailleux F; Haikala R; Ekström N; Eskola J; Yaich M; Käyhty H
    Vaccine; 2005 Nov; 23(46-47):5328-32. PubMed ID: 16118028
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Randomized study of early versus late immunization with pneumococcal conjugate vaccine after allogeneic stem cell transplantation.
    Cordonnier C; Labopin M; Chesnel V; Ribaud P; De La Camara R; Martino R; Ullmann AJ; Parkkali T; Locasciulli A; Yakouben K; Pauksens K; Einsele H; Niederwieser D; Apperley J; Ljungman P;
    Clin Infect Dis; 2009 May; 48(10):1392-401. PubMed ID: 19368505
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Vaccination with polysaccharide-conjugate-vaccines in adult patients with specific antibody deficiency.
    Shrimpton A; Duddridge M; Ziegler-Heitbrock L
    Vaccine; 2006 Apr; 24(17):3574-80. PubMed ID: 16507328
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Functional antibodies elicited by two heptavalent pneumococcal conjugate vaccines in the Finnish Otitis Media Vaccine Trial.
    Ekström N; Väkeväinen M; Verho J; Kilpi T; Käyhty H
    Infect Immun; 2007 Apr; 75(4):1794-800. PubMed ID: 17261612
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Estimating the protective concentration of anti-pneumococcal capsular polysaccharide antibodies.
    Siber GR; Chang I; Baker S; Fernsten P; O'Brien KL; Santosham M; Klugman KP; Madhi SA; Paradiso P; Kohberger R
    Vaccine; 2007 May; 25(19):3816-26. PubMed ID: 17368878
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Immunogenicity and reactogenicity of DTPa-IPV-HBV/Hib and DTPa-IPV/Hib vaccines coadministered with 7-valent pneumococcal conjugate vaccine as primary vaccination and booster in healthy infants, according to the French vaccination calendar].
    Reinert P; Dejos V; Clyti N; Abitbol V
    Arch Pediatr; 2008 Mar; 15(3):263-70. PubMed ID: 18272353
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.